World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
99
Citations
48203
World Ranking
8447
National Ranking
4367

Michael Charlton publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Michael Charlton sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 404 publications — 39th percentile

39% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Michael Charlton D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Michael Charlton sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 99 D-Index — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Michael Charlton is affiliated with the University of Chicago in the United States. Their research primarily focuses on medicine, with a significant body of work in epidemiology, hepatology, surgery, endocrinology, diabetes and metabolism, and infectious diseases.

Their publications span a broad range of topics related to liver diseases and metabolic conditions. The main topics of their research include:

  • Liver Disease Diagnosis and Treatment
  • Liver Disease and Transplantation
  • Diet, Metabolism, and Disease
  • Organ Transplantation Techniques and Outcomes
  • Liver Diseases and Immunity
  • Pancreatitis Pathology and Treatment
  • Hepatitis C virus research

Michael Charlton has contributed to a variety of scientific articles published in notable journals and venues. Some of the recent papers involving topics in liver disease and related fields are:

  • A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis (2024) published in New England Journal of Medicine
  • Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation (2020) published in Hepatology
  • Liver Transplantation 2023: Status Report, Current and Future Challenges (2023) published in Clinical Gastroenterology and Hepatology
  • Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance (2023) published in Journal of Hepatology
  • Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD (2022) published in Journal of Hepatology

The scientist frequently publishes in several leading journals, with the highest number of publications appearing in:

  • Journal of Hepatology (26 publications)
  • Gastroenterology (6 publications)
  • Transplantation (4 publications)
  • Clinical Gastroenterology and Hepatology (3 publications)
  • Liver Transplantation (3 publications)

Collaboration is a notable aspect of Michael Charlton's work, often co-authoring with researchers active in hepatology and related areas. Frequent co-authors include:

  • Naim Alkhouri (26 joint publications)
  • Mazen Noureddin (25 joint publications)
  • Jörn M. Schattenberg (21 joint publications)
  • Julie Dubourg (18 joint publications)
  • Thomas G. Cotter (16 joint publications)

The volume and diversity of Michael Charlton's research indicate extensive involvement in clinical and scientific inquiries related to liver diseases, metabolism, transplantation, and immunological factors affecting hepatic health.

Best Publications

  • The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

    Naga Chalasani;Zobair Younossi;Joel E. Lavine;Michael Charlton

  • The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

    Naga Chalasani;Zobair Younossi;Joel E. Lavine;Anna Mae Diehl

  • The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology

    Naga Chalasani;Zobair Younossi;Joel E. Lavine;Anna Mae Diehl

  • Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States

    Michael R. Charlton;Justin M. Burns;Rachel A. Pedersen;Kymberly D. Watt

  • Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis

    M. P. Curry;J. G. O'Leary;N. Bzowej;A. J. Muir

  • Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease

    Michael Charlton;Gregory T. Everson;Steven L. Flamm;Princy Kumar

  • Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study.

    Kymberly Ds Watt;Rachel A Pedersen;Walter K Kremers;Julie K Heimbach

  • Association of Non-Alcoholic Fatty Liver Disease With Chronic Kidney Disease: A Systematic Review and Meta-Analysis

    Giovanni Musso;Roberto Gambino;James H. Tabibian;Mattias Ekstedt

  • Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation

    David Goldberg;David Goldberg;Ivo C. Ditah;Kia Saeian;Mona Lalehzari

  • Predictors of patient and graft survival following liver transplantation for hepatitis C

    Michael Charlton;Eric Seaberg;Russell Wiesner;James Everhart

  • A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice.

    M.H. Khadra;R.S. Pickard;M. Charlton;P.H. Powell

  • The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial

    Rohit Loomba;Eric Lawitz;Parvez S. Mantry;Saumya Jayakumar

  • Nonalcoholic fatty liver disease: a review of current understanding and future impact.

    Michael Charlton

  • Lipid-Induced Signaling Causes Release of Inflammatory Extracellular Vesicles From Hepatocytes.

    Petra Hirsova;Samar H. Ibrahim;Anuradha Krishnan;Vikas K. Verma

  • Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis

    I. W. Graziadei;R. H. Wiesner;P. J. Marotta;M. K. Porayko

  • Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition

    Michael Charlton;Anuradha Krishnan;Kimberly Viker;Schuyler Sanderson

  • Recurrence of primary sclerosing cholangitis following liver transplantation

    Ivo W. Graziadei;Russell H. Wiesner;Kenneth P. Batts;Paul J. Marotta

  • Apolipoprotein synthesis in nonalcoholic steatohepatitis

    Michael Charlton;Raghavakaimal Sreekumar;Deborah Rasmussen;Keith Lindor

  • Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis

    Zobair M. Younossi;Rohit Loomba;Quentin M. Anstee;Mary Eugenia Rinella

  • Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation

    Michael Charlton;Edward Gane;Michael P. Manns;Robert S. Brown

Frequent Co-Authors

Rohit Loomba
Rohit Loomba University of California, San Diego
Nezam H. Afdhal
Nezam H. Afdhal Beth Israel Deaconess Medical Center
John G. McHutchison
John G. McHutchison Duke University
Gregory J. Gores
Gregory J. Gores Mayo Clinic
Zachary Goodman
Zachary Goodman Inova Fairfax Hospital
Stephen H. Caldwell
Stephen H. Caldwell University of Virginia
Zobair M. Younossi
Zobair M. Younossi Inova Health System
Anna Mae Diehl
Anna Mae Diehl Duke University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Choosing to study medicine in the USA can open doors to a range of related online degree programs and healthcare career pathways. For those interested in the business side of healthcare, pursuing financial aid for medical billing and coding can make entry into this high-demand field more affordable.

Nursing remains one of the most rewarding and flexible healthcare careers. Many aspiring nurses are now seeking nursing school that does not require teas test, making it easier to meet admission requirements and begin training quickly.

If your interests are in administration and leadership, an online health care administration degree can fast-track your journey to management roles in hospitals and health organizations.

For nurses with an ADN qualification, exploring adn to fnp bridge programs offers a flexible route to becoming a Family Nurse Practitioner, expanding career options and earning potential.

Best Scientists Citing Michael Charlton

Trending Scientists

Recently Published Articles